58P The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma

Epithelial ovarian cancer requires the development of treatments according to histology, and immune checkpoint inhibitors may be a new therapeutic strategy in clear cell carcinoma (OCCC). Lymphocyte activation gene 3 (LAG-3), an checkpoint, is poor prognostic factor target for several malignancies. In this study, we demonstrated correlation between LAG-3 expression clinicopathological features OCCC. We evaluated tumor-infiltrating lymphocytes (TILs) by immunohistochemistry using tissue microarrays containing surgically resected specimens from 171 patients with The LAG-3-positive cases were 48 (28.1%); LAG-3-negative 123 (71.9%). significantly increased advanced stages (P = 0.036) recurrence 0.012). However, did not correlate age 0.613), residual tumor 0.156), or death 0.086). Using Kaplan−Meier method, was observed correlated poorer overall survival 0.020) progression-free 0.019) than no expression. Multivariate analysis regarded (hazard ratio= 1.86; 95% confidence interval, 1.00−3.44, P 0.049) ratio 9.71; 5.13−18.52, < 0.001) as independent factors. This study that OCCC useful biomarker predicting prognosis target.